Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
Adjuvant olaparib (Lynparza) was linked with significantly longer life free of invasive or distant illness compared to placebo among patients with high-risk, HER2-negative early breast cancer and germline BRCA1 or BRCA2 pathogenic or possibly pathogenic mutations. Global patient-reported quality of life was not significantly impacted by olaparib.
Oncology, Medical January 23rd 2023
Cancer Therapy Advisor
In his discussion of the subject, Adam M. Brufsky, MD, PhD, FACP, of the University of Pittsburgh School of Medicine notes that about 50% of breast cancers categorized as HER2-negative exhibit low HER2 expression, and preliminary data suggest that new antibody-drug conjugates may be effective in treating tumors with low HER2 expression; clinical trials are currently underway. Trastuzumab should not be added to treatment plans for women with low HER2 expression, according to Dr. Brufsky, because it does not assist those with IHC 3+ or ISH-amplified breast cancer or those without those conditions. Finally, compared to triple-negative tumors, hormone receptor-positive (HR+)/HER2-negative cancers seem to have low HER2 expression more commonly.
Oncology, Medical January 17th 2023
MedPage Today
The majority of the decrease in the risk of local recurrence was seen in the first decade, according to the researchers’ observations of a differential effect over time. With or without irradiation, the risk of recurrence is not significantly different in the second decade. However, others pointed out that the goal of radiotherapy is not to increase overall survival but rather to lower the risk of local recurrence, which is a crucial aspect of breast-conserving therapy.
Oncology, Medical November 28th 2022
The median PFS and overall survival in the hormone receptor-positive cohort (494; 88.7%) were 23.9 months and 17.5 months, respectively, for the trastuzumab deruxtecan group and 10.1 months and 5.4 months, respectively, for the physician’s choice group. Overall survival was 23.4 months and 16.8 months, respectively, while the median PFS for all patients was 9.9 months for the trastuzumab deruxtecan group and 5.1 months for the physician’s choice group.
Oncology, Medical November 14th 2022
JAMA Network
The 100-μg dose of the ERBB2 ICD plasmid-based vaccine was associated with the generation of ERBB2-specific type 1 T cells in the majority of patients with ERBB2-expressing breast cancer in this phase 1 nonrandomized clinical trial, and it is currently being assessed in randomized phase 2 trials.
Oncology, Medical November 7th 2022
Cancer Therapy Advisor provides a variety of resources, including regimens used to supplement the most recent treatment strategies. Examine all regimens here.
Hematology/Oncology October 7th 2022